Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Molecular Partners
< Previous
1
2
Next >
Molecular Partners Announces all Board Proposals Approved at Annual General Meeting
April 16, 2025
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to hold three poster presentations at AACR 2025
March 25, 2025
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Publishes Invitation to Annual General Meeting 2025
March 25, 2025
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024
March 06, 2025
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call
February 28, 2025
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer
January 12, 2025
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference
January 12, 2025
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January
December 17, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
December 08, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
November 07, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition
November 05, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
October 31, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
October 25, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
October 22, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
October 22, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
October 04, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
September 27, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Reports H1 2024 Corporate Highlights and Financials
August 26, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
June 17, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
June 14, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
June 11, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
June 01, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
May 16, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action
April 29, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Life Science Cares Launches in Switzerland
April 19, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
April 17, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Publishes Invitation to Annual General Meeting 2024
March 26, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
March 14, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces Dismissal of Class Action Lawsuit
March 01, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
March 01, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit